Recent takeover activity suggests these diagnostic companies may be significantly undervalued. Their innovative technologies could be worth much more to potential acquirers than current market prices suggest.
When acquisition offers are announced, target company stocks often surge dramatically. Being invested before a takeover bid is announced could mean substantial quick gains if a company becomes the next target.
The OraSure takeover bid signals that industry insiders see tremendous value in diagnostic technologies. Smart money is already positioning for more consolidation in this rapidly evolving healthcare sector.
Summary of the basket's total market capitalisation and investor takeaways.
FLGT: $733.70M
QDEL: $2.03B
EXAS: $12.00B
Recent unsolicited takeover bids in the diagnostics sector suggest smaller specialized companies may be undervalued. As healthcare consolidation accelerates, firms with innovative technologies in areas like molecular diagnostics, genetic sequencing, and at-home testing look particularly attractive to larger players seeking growth.
This is a tactical, event-driven opportunity focused on small to mid-cap diagnostic companies. When one company receives a takeover offer, it often triggers a sector-wide re-evaluation as investors look for the next potential target with similar valuable technological assets.
These companies were specifically selected because they possess unique technological capabilities, established market presence, and innovative testing solutions. Each represents a potential acquisition target for larger healthcare conglomerates looking to expand their diagnostic portfolios.
This carefully selected group of stocks features innovative diagnostic companies that could become acquisition targets following recent takeover interest in the sector. Professional analysts have identified these companies for their unique technologies and established market positions in a consolidating healthcare landscape.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
+4
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
BHP Group recently posted a massive earnings beat driven by record copper profitability, allowing the miner to raise its dividend to a four-year high. This performance highlights a structural shift toward electrification metals, creating opportunities for industrial equipment suppliers and competing copper producers.
Here are a few of the assets in this group. Create an account to unlock the full list.
FULGENT GENETICS INC
FLGT
Current Price
$19.76
A technology-driven genetics company offering a broad suite of tests. Its comprehensive testing platform and bioinformatics capabilities make it a pot...
A technology-driven genetics company offering a broad suite of tests. Its comprehensive testing platform and bioinformatics capabilities make it a potentially attractive target for a larger diagnostics or life sciences company looking to expand its genetic testing menu.
QUIDELORTHO CORPORATION
QDEL
Current Price
$14.04
A major provider of rapid diagnostic testing solutions. Following its merger with Ortho Clinical Diagnostics, its expanded portfolio in point-of-care ...
A major provider of rapid diagnostic testing solutions. Following its merger with Ortho Clinical Diagnostics, its expanded portfolio in point-of-care and immunoassay testing could be of interest to a strategic buyer seeking scale and diversification.
GUARDANT HEALTH INC
GH
Current Price
$161.33
A precision oncology company focused on liquid biopsy tests for cancer. Its advanced blood-testing technology for guiding cancer treatment and monitor...
A precision oncology company focused on liquid biopsy tests for cancer. Its advanced blood-testing technology for guiding cancer treatment and monitoring recurrence is a high-growth area that could attract acquisition interest from established players in the oncology space.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+49.65%
On average, analysts expect assets in this group to grow 49.65% over the next year.
8 of 12 assets in this group are rated Buy by professional analysts.
